Cambridge Biotech Corp. of Worcester, Mass., has signed anagreement with Gull Laboratories Inc. of Salt Lake City tomanufacture its line of 15 enzyme immunoassay diagnostic kitsunder Cambridge Biotech's name.

The kits are most commonly used by hospitals and laboratoriesto screen for early- or late-stage infections withcytomegalovirus, Epstein-Barr virus, Herpes simplex virus andmeasles virus, as well as Lyme disease and toxoplasmosis. Thekits will augment Cambridge Biotech's existing lines ofdiagnostic products, which are focused primarily on HIV, saidCambridge spokeswoman Christina Pappas.

Cambridge shares (NASDAQ:CBCX) closed Monday at $11.25,down 63 cents.

(c) 1997 American Health Consultants. All rights reserved.